104 related articles for article (PubMed ID: 31599852)
1. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition.
Harvey M; Prosser LA; Rose AM; Ortega-Sanchez IR; Harpaz R
Pain; 2020 Feb; 161(2):361-368. PubMed ID: 31599852
[TBL] [Abstract][Full Text] [Related]
2. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
4. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A
Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic implications of increasing access to herpes zoster vaccination rate in community pharmacies.
Watanabe AH; Veettil SK; Le LM; Bald E; Tak C; Chaiyakunapruk N
J Am Pharm Assoc (2003); 2023; 63(5):1530-1538. PubMed ID: 37207710
[TBL] [Abstract][Full Text] [Related]
6. Health care utilization and cost burden of herpes zoster in a community population.
Yawn BP; Itzler RF; Wollan PC; Pellissier JM; Sy LS; Saddier P
Mayo Clin Proc; 2009 Sep; 84(9):787-94. PubMed ID: 19720776
[TBL] [Abstract][Full Text] [Related]
7. The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.
Gater A; Uhart M; McCool R; Préaud E
BMC Public Health; 2015 Feb; 15():193. PubMed ID: 25880058
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.
Florea A; Sy L; Qian L; Ackerson B; Luo Y; Wu J; Cheng Y; Ku J; Vega Daily L; Takhar H; Song J; Chmielewski-Yee E; Spence O; Seifert H; Oraichi D; Tseng HF
Hum Vaccin Immunother; 2024 Dec; 20(1):2327145. PubMed ID: 38488143
[TBL] [Abstract][Full Text] [Related]
9. Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials.
Giannelos N; Francq B; Curran D
Clin Drug Investig; 2024 May; 44(5):293-301. PubMed ID: 38662318
[TBL] [Abstract][Full Text] [Related]
10. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis.
Le P; Rothberg MB
J Gen Intern Med; 2017 Feb; 32(2):159-167. PubMed ID: 27743284
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and economic burden of hospitalized patients with herpes zoster in China, before vaccination.
Chen P; Chen Z; Xiao Y; Chen X; Li J; Tang Y; Shen M
Hum Vaccin Immunother; 2023 Dec; 19(3):2268990. PubMed ID: 37899682
[TBL] [Abstract][Full Text] [Related]
12. Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia.
Han R; San Martin P; Ahmed N; Guzman-Holst A; Mohy A; Pinto T; de Veras B; Gomez JA; Bibera GL; van Oorschot DAM
Infect Dis Ther; 2024 Apr; 13(4):761-778. PubMed ID: 38493411
[TBL] [Abstract][Full Text] [Related]
13. Incidence of herpes zoster and associated events including stroke--a population-based cohort study.
Sundström K; Weibull CE; Söderberg-Löfdal K; Bergström T; Sparén P; Arnheim-Dahlström L
BMC Infect Dis; 2015 Oct; 15():488. PubMed ID: 26520060
[TBL] [Abstract][Full Text] [Related]
14. A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific.
Chen J; Abrahamson PE; Ke Y; Ong CR; Parikh R; Shantakumar S
Hum Vaccin Immunother; 2024 Dec; 20(1):2344983. PubMed ID: 38767209
[TBL] [Abstract][Full Text] [Related]
15. Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Miyun District of Beijing, China: An EQ-5D survey.
Zhao D; Suo L; Lu L; Pan J; Peng X; Wang Y; Pang X
Vaccine X; 2023 Dec; 15():100415. PubMed ID: 38124774
[TBL] [Abstract][Full Text] [Related]
16. Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost.
Singer D; Thompson-Leduc P; Ma S; Gupta D; Cheng WY; Muthukumar A; Devine F; Sundar M; Bogart M; Hagopian E; Poston S; Duh MS; Oppenheimer JJ
BMJ Open Respir Res; 2024 Jun; 11(1):. PubMed ID: 38862238
[TBL] [Abstract][Full Text] [Related]
17. Evaluating public interest in herpes zoster in Germany by leveraging the internet: a retrospective search data analysis.
Kain A; Tizek L; Wecker H; Wallnöfer F; Biedermann T; Zink A
BMC Public Health; 2023 Aug; 23(1):1546. PubMed ID: 37580664
[TBL] [Abstract][Full Text] [Related]
18. A cross-sectional survey of work and income loss consideration among patients with herpes zoster when completing a quality of life questionnaire.
Johnson KD; Brenneman SK; Newransky C; Sheffler-Collins S; Becker LK; Belland A; Acosta CJ
BMC Health Serv Res; 2018 Aug; 18(1):662. PubMed ID: 30144806
[TBL] [Abstract][Full Text] [Related]
19. Is herpes zoster vaccination likely to be cost-effective in Canada?
Peden AD; Strobel SB; Forget EL
Can J Public Health; 2014 May; 105(4):e287-95. PubMed ID: 25166132
[TBL] [Abstract][Full Text] [Related]
20. Herpes zoster in older adults: Impact on carbon footprint in the United States.
Curran D; Bitetti J; Catterall I; Wincott S
Hum Vaccin Immunother; 2024 Dec; 20(1):2335722. PubMed ID: 38698759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
